Heaves hit for Stirling
Tuesday, 29 July, 2008
Stirling Products [ASX: STI] has been granted an Australian patent or the treatment of heaves in horses with R-salbutamol.
The company has already been granted a patent for the same concept from South Africa, and Stirling representatives say they expect more grants to follow shortly.
A patent application for the inhaler device developed to help administer the drug, the Equinehaler, has also been lodged.
Heaves, also known as recurrent airway obstruction, affects an estimated 25-30 per cent of all horses in Europe and the US.
Stirling is also looking at using R-salbutamol - a highly purified version of salbutamol, better known as Ventolin - as a growth agent and as a treatment of obesity in dogs.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
